Literature DB >> 8703885

Causes and frequency of blindness in patients with intraocular inflammatory disease.

A Rothova1, M S Suttorp-van Schulten, W Frits Treffers, A Kijlstra.   

Abstract

AIMS/
BACKGROUND: Uveitis, an intraocular inflammatory disease, is a significant cause of visual impairment. It is not known how many patients with uveitis will retain visual acuity and how many develop visual impairment or even blindness. The aim of this study was to assess the frequency of blindness in patients with uveitis and, more specifically, to identify the clinical profile of patients at risk for visual loss.
METHODS: A cross sectional and retrospective study of 582 patients with uveitis who visited the ophthalmology departments of two university hospitals in the Netherlands was performed.
RESULTS: Within the group of 582 patients, 203 (35%) exhibited blindness or visual impairment; bilateral legal blindness developed in 22 (4%) patients, 26 (4.5%) had one blind eye with visual impairment of the other, and nine (1.5%) had bilateral visual impairment. Unilateral blindness developed in 82 (14%) patients, whereas 64 (11%) exhibited unilateral visual impairment. The most important cause of both blindness and visual impairment was cystoid macular oedema (29% and 41%, respectively). Complications of uveitis were encountered in more than half of the patients and 23% underwent one or more surgical procedures. When the patients were subdivided according to anatomical site, those with panuveitis had the worst visual prognosis. The systemic diseases associated with a poor visual prognosis were juvenile chronic arthritis and sarcoidosis. Ocular toxoplasmosis was the most frequent cause of unilateral visual loss.
CONCLUSIONS: Cystoid macular oedema is the most frequent complication of uveitis and its occurrence plays a decisive role in the visual outcome of this disease.

Entities:  

Mesh:

Year:  1996        PMID: 8703885      PMCID: PMC505460          DOI: 10.1136/bjo.80.4.332

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  30 in total

Review 1.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

2.  Toxoplasmosis: the time has come.

Authors:  R McCabe; J S Remington
Journal:  N Engl J Med       Date:  1988-02-04       Impact factor: 91.245

3.  Birdshot chorioretinopathy: clinical characteristics and evolution.

Authors:  H A Priem; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1988-09       Impact factor: 4.638

4.  International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease.

Authors:  E Bloch-Michel; R B Nussenblatt
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

5.  Causes of blindness in The Netherlands.

Authors:  J ten Doesschate
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

6.  Serology in ocular toxoplasmosis.

Authors:  A Rothova; F van Knapen; G S Baarsma; P J Kruit; D H Loewer-Sieger; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

7.  Prognostic factors in the uveitis of juvenile rheumatoid arthritis.

Authors:  M D Wolf; P R Lichter; C G Ragsdale
Journal:  Ophthalmology       Date:  1987-10       Impact factor: 12.079

8.  A follow-up study on serpiginous choroiditis.

Authors:  L Laatikainen; H Erkkilä
Journal:  Acta Ophthalmol (Copenh)       Date:  1981-10

9.  Risk factors for ocular sarcoidosis.

Authors:  A Rothova; C Alberts; E Glasius; A Kijlstra; H J Buitenhuis; A C Breebaart
Journal:  Doc Ophthalmol       Date:  1989-08       Impact factor: 2.379

10.  Clinical features of acute anterior uveitis.

Authors:  A Rothova; W G van Veenedaal; A Linssen; E Glasius; A Kijlstra; P T de Jong
Journal:  Am J Ophthalmol       Date:  1987-02-15       Impact factor: 5.258

View more
  229 in total

Review 1.  Macular oedema: the role of soluble mediators.

Authors:  D Kent; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 2.  Management of chronic uveitis.

Authors:  P J McCluskey; H M Towler; S Lightman
Journal:  BMJ       Date:  2000-02-26

Review 3.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

Review 4.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

5.  Why HLA-B27? My thirty-year quest: the Friedenwald lecture.

Authors:  James T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-29       Impact factor: 4.799

6.  Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease.

Authors:  Leorey N Saligan; Grace Levy-Clarke; Tongtong Wu; Lisa J Faia; Keith Wroblewski; Steven Yeh; Robert B Nussenblatt; H Nida Sen
Journal:  Ophthalmic Epidemiol       Date:  2010-08       Impact factor: 1.648

7.  Tertiary Lymphoid Tissue Forms in Retinas of Mice with Spontaneous Autoimmune Uveitis and Has Consequences on Visual Function.

Authors:  Jennifer L Kielczewski; Reiko Horai; Yingyos Jittayasothorn; Chi-Chao Chan; Rachel R Caspi
Journal:  J Immunol       Date:  2015-12-28       Impact factor: 5.422

8.  Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants.

Authors:  Gabriella M Fernandes-Cunha; Cíntia M F Rezende; Wagner N Mussel; Gisele R da Silva; Elionai C de L Gomes; Maria I Yoshida; Sílvia L Fialho; Alfredo M Goes; Dawison A Gomes; Ricardo W de Almeida Vitor; Armando Silva-Cunha
Journal:  J Mater Sci Mater Med       Date:  2015-12-16       Impact factor: 3.896

9.  Angiogenic and Immunologic Proteins Identified by Deep Proteomic Profiling of Human Retinal and Choroidal Vascular Endothelial Cells: Potential Targets for New Biologic Drugs.

Authors:  Justine R Smith; Larry L David; Binoy Appukuttan; Phillip A Wilmarth
Journal:  Am J Ophthalmol       Date:  2018-03-17       Impact factor: 5.258

10.  Neoplastic masquerade syndromes in patients with uveitis.

Authors:  Landon K Grange; Amr Kouchouk; Monica D Dalal; Susan Vitale; Robert B Nussenblatt; Chi-Chao Chan; H Nida Sen
Journal:  Am J Ophthalmol       Date:  2013-11-06       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.